High-purity substrates for enzyme detection and assay performance
Agilent Advanced Therapeutics supplies a range of diagnostic and molecular biology reagents designed for enzyme detection, immunodiagnostic applications, and analytical assay development. These substrates support the detection of carboxylase, alkaline phosphatase, and other diagnostic enzymes, as well as cell proliferation analysis. Products include phosphoenolpyruvate derivatives (PEP-K and PEP-Tri), pNPP-ditris for alkaline phosphatase assays, BCIP-T for immunodiagnostic applications, and XTT for toxicity and proliferation assays. Each substrate is produced with stringent quality controls to support consistent analytical outcomes, robust assay performance, and reproducible results across research, QC testing, and diagnostic environments.
High-purity substrates—Consistent quality for enzyme detection and diagnostic workflows.
Broad assay compatibility—Supports immunoassays, cell-based assays, and enzyme activity tests.
Reliable analytical performance—Formulated for reproducibility across batches and testing sites.
Suitable for diagnostic enzymes—Substrates for carboxylase, alkaline phosphatase, and others.
Flexible application range—Ideal for R&D, QC labs, and diagnostic kit manufacturing.
Produced under strict QC—Ensures consistent assay performance and regulatory confidence.
Diagnostic and Molecular Biology Reagents
High-purity substrates for diagnostic enzyme detection and molecular biology assays
Find helpful answers to common questions as you evaluate and advance your program
What grades do your bioprocessing reagents come in?
Our portfolio includes multiple quality grades to support different development stages. Research and molecular biology (MBG) grades are well suited for early studies, assay development, or non-GMP workflows. cGMP-grade materials, including TCEP, DHAA, and select reductants, are manufactured under strict quality controls to support GMP manufacturing, regulatory filings, and commercial programs. Specifications vary by reagent.
Are these reagents suitable for microbial fermentation?
Yes, several products directly support microbial expression workflows. Reagents like IPTG (non-animal origin) are specifically used for induction in microbial fermentation processes, while others such as reductants and oxidants support downstream processing and purification. All materials are available in sizes appropriate for R&D through commercial manufacturing.
Do your cGMP-grade reagents support ADC manufacturing?
Yes, our cGMP TCEP and cGMP DHAA are widely used in ADC programs as complementary redox partners. TCEP provides stable, irreversible reduction without metal interference, while DHAA offers high stability and efficient oxidation for improved yields. Both are manufactured under strict QC for regulatory readiness.
What scale of material can you supply?
We offer flexible supply options to support early development, pilot runs, and commercial programs. Most reagents can be ordered in small research volumes or scaled to multi-kilogram quantities appropriate for GMP manufacturing and long-term production campaigns.
style
id
faqs
Browse the latest news on Advanced Therapeutics manufacturing
BIOVECTRA Is Honored with 2025 CDMO Leadership Award
BIOVECTRA, a part of Agilent Technologies Inc., proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as quality, reliability, and technical capability.
3/6/2025
Agilent Completes Acquisition of BIOVECTRA
Agilent Technologies announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
9/20/2024
Agilent Investing $725 Million to Expand Nucleic Acid-Based Therapeutics Manufacturing
Agilent Technologies is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (APIs).
1/10/2023
id
news
id
videos
Innovative sustainability in water, waste, and energy
The Frederick facility integrates sustainable practices, like closed-cell cooling towers and reverse osmosis systems that save over 16 million gallons of water annually. A solar photovoltaic array generates 500 MWh of clean energy to offset utility demand. Waste reduction initiatives include acetonitrile recovery and destruction of dilute organics.
id
sustainability
Explore ways to connect with the Advanced Therapeutics team
Have questions or need a quote? Our manufacturing experts are here to help.
Get support from experienced specialists dedicated to your program’s success.
Upcoming events
See where the Agilent Advanced Therapeutics team will be next. Explore our upcoming conferences, tradeshows, and speaking engagements, and connect with us in person.
